LongevityLeak

NAD+ precursor therapy

NMN

Human trials show NAD-pathway and insulin-sensitivity signals, while functional outcomes remain mixed and mostly short-term.

Evidence Level B

Evidence and Risk Labels

Evidence A/B/C reflects research maturity, and risk levels reflect monitoring needs. These labels support comparison, not diagnosis or treatment decisions.

See full scoring guide

Clinical Snapshot

Effect Size
Biomarker improvements with variable clinical outcome gains
Safety
Moderate Risk

Stability and purity vary by brand.

Research Dosing

This reflects common ranges and protocols used in published studies, not personal medical advice.

Typical Daily Dose
250-600 mg
Timing
Morning or split morning/noon dosing
Protocol Duration in Studies
4-12 weeks in most current human studies

Clinical protocols often begin at 250 mg and adjust based on tolerance and biomarker goals.

Best Fit Profiles

  • NAD restoration programs

Source Links